Clinical applications of research on angiogenesis

New England Journal of Medicine

Volumn 333, Issue 26, 1995, Pages 1757-1763

  Flier, Jeffrey S ^a   Underhill, Lisa H ^a   Folkman, Judah ^b  

^a Children's Hospital ^*

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ANGIOGENIC FACTOR; ACIDIC FIBROBLAST GROWTH FACTOR; ALPHA INTERFERON; ANGIOGENIN; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BATIMASTAT; CORTICOSTEROID; FUMAGILLOL CHLOROACETYLCARBAMATE; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERFERON; INTERLEUKIN 8; MARIMASTAT; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PROLACTIN; PROLIFERIN; ROQUINIMEX; SCATTER FACTOR; SUCRALFATE; TECOGALAN; THALIDOMIDE; THROMBOCYTE FACTOR 4; THROMBOSPONDIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN;

HEMANGIOMA; HUMAN; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; REVIEW; ANGIOGENESIS; ARTHRITIS; ARTICLE; CANCER; CELL PROLIFERATION; CLINICAL TRIAL; DUODENUM ULCER; METASTASIS POTENTIAL; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; TUMOR VASCULARIZATION; WOUND HEALING;

ANGIOGENESIS INDUCING AGENTS; HEMANGIOMA; HUMANS; INTERFERON ALFA-2A; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84975525035     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199512283332608     Document Type: Review

References (50)

1. Folkman J. Tumor angiogenesis. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA, eds. The molecular basis of cancer. Philadelphia: W.B. Saunders, 1995:206-32.
2. Folkman J Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186
3. Folkman J angiogenesis in cancer, vascular, rheumatoid, and other disease. Nat Med 1995; 1: 27-31
4. Holmgren L, O'Reilly MS, Folkman J Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1: 149-153
5. Dameron KM, Volpert OV, Tainsky MA, Bouck N control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-1584
6. Folkman J. Tumor angiogenesis. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer medicine. 3rd ed. Vol. 1. Philadelphia: Lea & Febiger, 1993:153-70.
7. Jackson D, Volpert OV, Bouck N, Linzer DIH Stimulation and inhibition of angiogenesis by placental proliferin and proliferin-related protein. Science 1994; 266: 1581-1584
8. Pepper MS, Ferrara N, Orci L, Montesano R Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992; 189: 824-831
9. Clapp C, Martial JA, Guzman RC, Rentier-Delure F, Weiner RI the 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 1993; 133: 1292-1299
10. Hanneken A, Ying W, Ling N, Baird A Identification of soluble forms of the fibroblast growth factor receptor in blood. Proc Natl Acad Sci U S A 1994; 91: 9170-9174
11. Jaffe EA Cell biology of endothelial cells. Hum Pathol 1987; 18: 234-239
12. Denekamp J Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993; 66: 181-196
13. Brooks PC, Clark RAF, Cheresh DA Requirement of vascular integrin αvβ3 for angiogenesis. Science 1994; 264: 569-571
14. Rak JW, St Croix BD, Kerbel RS Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs 1995; 6: 3-18
15. O'Reilly MS, Holmgren L, Shing Y, Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328
16. Teicher BA, Holden SA, Ara G, Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 1994; 57: 920-925
17. Miller JW, Adamis AP, Shima DT, Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994; 145: 574-584
18. Aiello LP, Avery RL, Arrigg PG, Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487
19. Dvorak HF, Brown LF, Detmar M, Dvorak AM Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-1039
20. Shweiki D, Itin A, Soffer D, Keshet E Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-845
21. O'Brien ER, Garvin MR, Dev R, Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol 1994; 145: 883-894
22. Stavri GT, Hong Y, Zachary IC, Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells. FEBS Lett 1995; 358: 311-315
23. Peacock DJ, Banquerigo ML, Brahn E Angiogenesis inhibition suppresses collagen arthritis. J Exp Med 1992; 175: 1135-1138
24. Nickoloff BJ, Mitra RS, Varani J, Dixit VM, Polverini PJ Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 1994; 144: 820-828
25. Bacharach-Buhles M, Panz B, el Gammal S, Auer T, Altmeyer P The elongation of psoriatic capillaries, the result of epidermal hyperplasia, not of angiogenesis. J Invest Dermatol 1994; 103: 263-263 abstract.
26. Folkman J, Szabo S, Stovroff M, McNeil P, Li W, Shing Y Duodenal ulcer: discovery of a new mechanism and development of angiogenic therapy which accelerates healing. Ann Surg 1991; 214: 414-427
27. Hull MA, Cullen DJE, Hawkey CJ Basic fibroblast growth factor in gastric ulceration: mucosal levels and therapeutic potential. Gastroenterology 1994; 106: Suppl: A97-A97 abstract.
28. Wolfe MM, Bynum TE, Parsons WG, Malone KM, Szabo S, Folkman J Safety and efficacy of an angiogenic peptide, basic fibroblast growth factor (bFGF), in the treatment of gastroduodenal ulcers: a preliminary report. Gastroenterology 1994; 106: Suppl: A212-A212 abstract.
29. Folkman J. Angiogenesis in female reproductive organs. In: Alexander NH, d'Arcangues C, eds. Steroid hormones and uterine bleeding. Washington, D.C.: AAAS Press, 1992:143-58.
30. Weidner N, Semple JP, Welch WR, Folkman J Tumor angiogenesis and metastasis -- correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8
31. Weidner N Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995; 147: 9-19
32. Folkman J Angiogenesis and breast cancer. J Clin Oncol 1994; 12: 441-443
33. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994; 86: 356-361
34. Li VW, Folkerth RD, Watanabe H, Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet 1994; 344: 82-86
35. Mulliken JB, Young AE. Vascular birthmarks: hemangiomas and malformations. Philadelphia: W.B. Saunders, 1988.
36. White CW, Sondheimer HM, Crouch EC, Wilson H, Fan LL Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med 1989; 320: 1197-1200
37. Ezekowitz RAB, Mulliken JB, Folkman J Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992; 326: 1456-1463 [Erratum, N Engl J Med 1994;330:300; 1995;333:595-6.]
38. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ Interferons α and β down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A 1995; 92: 4562-4566
39. D'Amato RJ, Loughnan MS, Flynn E, Folkman J thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994; 91: 4082-4085
40. Guerin C, Laterra J, Masnyk T, Golub LM, Brem H Selective endothelial growth inhibition by tetracyclines that inhibit collagenase. Biochem Biophys Res Commun 1992; 188: 740-745
41. Paulus HE Minocycline treatment of rheumatoid arthritis. Ann Intern Med 1995; 122: 147-148
42. Ingber D, Fujita T, Kishimoto S, Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348: 555-557
43. Kahn J, Ruiz R, Kershmann R, A Phase I/II study of recombinant platelet factor (rPF4) in patients with AIDS related Kaposi's sarcoma (KS). Proc Am Soc Clin Oncol 1993; 12: 50-50 abstract.
44. Kohn EC, Alessandro R, Spoonster J, Wersto RP, Liotta LA Angiogenesis: role of calcium-mediated signal transduction. Proc Natl Acad Sci U S A 1995; 92: 1307-1311
45. Beattie GJ, Young HA, Smyth JF Phase I study of intra-peritoneal metallo-proteinase inhibitor BB94 in patients with malignant ascites. Ann Oncol 1994; 5: Suppl 5: 72-72 abstract.
46. Drummond AH, Beckett P, Bone EA, BB-2516: an orally bioavailable matrix metalloproteinase inhibitor with efficacy in animal cancer models. Proc Am Assoc Cancer Res 1995; 36: 100-100 abstract.
47. Tulpule A, Snyder JC, Espina BM, A phase I study of tecogalan, a novel angiogenesis inhibitor in the treatment of AIDs-related Kaposi's sarcoma and solid tumors. Blood 1994; 84: Suppl 1: 248a-248a abstract.
48. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87: 581-586
49. Vukanovic J, Passaniti A, Hirata T, Traystmann RJ, Hartley-Asp B, Isaacs JT Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res 1993; 53: 1833-1837
50. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, Steeg PS Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 1994; 54: 6504-6511